Singapore-based healthtech startup Mesh Bio has raised $1.8 million (SGD2.4 million) in Seed funding, led by deep tech investors Elev8.vc and Enterprise Singapore’s investment arm Seeds Capital, along with Citrine Capital and Tael Partners.

The funds will be used to accelerate the rollout of Mesh Bio’s solution, DARA® - a predictive analytics and clinical workflow automation solution for healthcare providers - in Southeast Asia and Hong Kong. The funding will also support clinical partnerships and collaborations.

“Our vision is to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region. Through the support of Elev8.vc, Seeds Capital, Citrine Capital and Tael Partners, we see tremendous opportunity to help healthcare providers cope with the rise in cases and simultaneously, improve patient treatment and outcomes with DARA®,” said Andrew Wu, Mesh Bio Co-founder, and CEO.

DARA® draws in real-time, multidimensional patient data: health history, lab tests and medical images. DARA® delivers a patient-centric visual report, helping doctors counsel patients and allowing patients to understand their laboratory reports, and the diseases they live with.

In-built with clinical best practices, guidelines and holistic patient assessments, DARA® helps doctors leverage knowledge from the global community of healthcare practitioners. Its risk assessment algorithms are compliant with local clinical practice guidelines. Other key features include: multiple diseases in one report;  

1. quantifiable risk contributors;
2. Up to 10 years risk projection;  
3. and clinical as well as actionable lifestyle recommendations.

DARA® has helped healthcare providers in Singapore analyse patient data quickly and effectively, increasing report generation by five times and reducing human error. The solution has delivered over 60 percent in operational savings and 99 percent in revenue growth.